| Methods:The experiment selects Sprague-Dawley (SD) mouse, divides into five groups stochastically: The sham-operation group, the model group, the L-dopamine (LD) group (the LD group), the Shujin Jiedu Prescription large dose group (the SJL group), the Shujin Jiedu Prescription middle dose group (the SJM group) and the Shujin Jiedu Prescription small dose group (the SJS group). Uses in the brain three-dimensional localization opsoninum to inject 6-OHDA to establish the PD big mouse model, has carried on the PD big mouse behavior study observation separately; applies the high peformance liquid chromatography (HPLC) examines PD big mouse opsoninum corpus striatum DA and the metabolite homovanillic acid (HVA), 3,4-dihydroxy phenylacetic acids (DOPAC) content; application in situ hybridization(ISH) examines PD the big mouse opsoninum corpus striatum Bcl-2mRNA/BaxmRNA distribution and the expression.The experimental results:1 The impact of the Shujin Jiedu Prescription on PD mouse behavior studyThe LD group and SJL, SJM group may alleviate the PD mouse's revolving behavior effectively, with the model group, the SJS group comparison has statistics difference (P<0.01); the SJL,SJM group may improve the PD mouse's exceptionally dependent movement obviously, has statistics difference with the LD group comparison (P<0.01).2 The impact of the Shujin Jiedu Prescription on PD mouse DA and metabolitesHPLC showed: Compares with other each group of PD mouse corpus striatum with the sham-operation group the DA content to reduce, has statistics difference(P<0.01). The LD group, SJL, SJM group PD the mouse opsoninum corpus striatum DA content markup and the model group and the SJS group comparison has statistics difference (P<0.05).LD group PD mouse,the HVA content advances, the DA/HVA ratio reduces; SJL, SJM group DOPAC, the HVA content reduces, the DA/HVA ratio rise to the normal level, has statistics difference with the LD group comparison(P<0.05) .3 The impact of the Shujin Jiedu Prescription on PD mouse substantia nigra in the expression of Bcl-2mRNA/BaxmRNAISH results showed: the model group and the LD group the Department of substantia nigra Bcl-2mRNA, baxmRNA expression were significantly higher dose Shujin antidote to large and medium-sized group of the Department of substantia nigra expression of Bcl-2mRNA were significantly increased, while BaxmRNA expression was significantly lower, and of Bcl-2mRNA, BaxmRNA expression with dose-effect relationship.Conclusion:1 The Shujin Jiedu Prescription alleviates the PD mouse's revolving behavior, what is different with the LD group is that has the distinct improvement function to the PD big mouse's exceptionally dependent movement, whith prompts The Shujin Jiedu Prescription different with LD to the PD big mouse's function mechanism, it possibly through adjusts in the PD mouse cranial nerve quenching and tempering, the adjustment mesencephalon dopamine acceptor's distribution and the sensitivity, thus achieves raises the mesencephalon DA level, the protection dopamine to be able the neuron, improves the PD symptom the function.2 The results suggest that with the department of protection of substantia nigra DA neurons in the role, and DA replacement therapy drugs of different mechanisms, it may be through the promotion of rat model of Parkinson's disease substantia nigra damage to adjacent striated body secretion, while inhibiting DA decomposition so as to enhance the endogenous catecholamine content of the material to reach its therapeutic. Dose range with positive correlation.3 The Shujin Jiedu Prescription may be able to increase the level of inhibitor of apoptosis through Bcl-2mRNA, reduced transfer factor promoting BaxmRNA from genes level, thereby increasing the ratio of Bcl-2mRNA/BaxmRNA to inhibit PD midbrain dopamine neuronal apoptosis, reduced dopaminergic The purpose of the loss of neurons, which in varying degrees to protect dopamine neurons, slowing the progress of PD pathogenesis.
|
PDF Full Text Request